Your browser doesn't support javascript.
Pediatric bowel preparation: Sodium picosulfate, magnesium oxide, citric acid vs polyethylene glycol, a randomized trial.
Cuffari, Carmen; Ciciora, Steven L; Ando, Masakazu; Boules, Mena; Croffie, Joseph M.
  • Cuffari C; Department of Pediatrics, The Johns Hopkins School of Medicine, Baltimore, MD 21287, United States. ccuffari@jhmi.edu.
  • Ciciora SL; Department of Pediatrics, The Ohio State University College of Medicine, Colombus, OH 43205, United States.
  • Ando M; Department of Statistics, Ferring Pharmaceuticals Inc, Parsippany, NJ 07054, United States.
  • Boules M; Department of Medical Affairs, Ferring Pharmaceuticals Inc, Parsippany, NJ 07054, United States.
  • Croffie JM; Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN 46202, United States.
World J Gastroenterol ; 26(40): 6260-6269, 2020 Oct 28.
Article in English | MEDLINE | ID: covidwho-1302599
ABSTRACT

BACKGROUND:

Bowel preparation in children can be challenging.

AIM:

To describe the efficacy, safety, and tolerability of sodium picosulfate, magnesium oxide, and citric acid (SPMC) bowel preparation in children.

METHODS:

Phase 3, randomized, assessor-blinded, multicenter study of low-volume, divided dose SPMC enrolled children 9-16 years undergoing elective colonoscopy. Participants 9-12 years were randomized 111 to SPMC ½ dose × 2, SPMC 1 dose × 2, or polyethylene glycol (PEG). Participants 13-16 years were randomized 11 to SPMC 1 dose × 2 or PEG. PEG-based bowel preparations were administered per local protocol. Primary efficacy endpoint for quality of bowel preparation was responders (rating of 'excellent' or 'good') by modified Aronchick Scale. Secondary efficacy endpoint was participant's tolerability and satisfaction from a 7-item questionnaire. Safety assessments included adverse events (AEs) and laboratory evaluations.

RESULTS:

78 participants were randomized, 48 were 9-12 years, 30 were 13-16 years. For the primary efficacy endpoint in 9-12 years, 50.0%, 87.5%, and 81.3% were responders for SPMC ½ dose × 2, SPMC 1 dose × 2, and PEG groups, respectively. Responder rates for 13-16 years were 81.3% for SPMC 1 dose × 2 and 85.7% for PEG. Overall, 43.8% of participants receiving SPMC 1 dose × 2 reported it was 'very easy' or 'easy' to drink, compared with 20.0% receiving PEG. Treatment-emergent AEs were reported by 45.5% of participants receiving SPMC 1 dose × 2 and 63.0% receiving PEG.

CONCLUSION:

SPMC was an efficacious and safe for bowel preparation in children 9-16 years, with comparable efficacy to PEG. Tolerability for SPMC was higher compared to PEG.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Organometallic Compounds / Magnesium Oxide Type of study: Experimental Studies / Observational study / Randomized controlled trials Limits: Child / Humans Language: English Journal: World J Gastroenterol Journal subject: Gastroenterology Year: 2020 Document Type: Article Affiliation country: Wjg.v26.i40.6260

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Organometallic Compounds / Magnesium Oxide Type of study: Experimental Studies / Observational study / Randomized controlled trials Limits: Child / Humans Language: English Journal: World J Gastroenterol Journal subject: Gastroenterology Year: 2020 Document Type: Article Affiliation country: Wjg.v26.i40.6260